ZA200902187B - 8-Ethinylxanthine derivatives as selective A2A receptor antagonists - Google Patents

8-Ethinylxanthine derivatives as selective A2A receptor antagonists

Info

Publication number
ZA200902187B
ZA200902187B ZA200902187A ZA200902187A ZA200902187B ZA 200902187 B ZA200902187 B ZA 200902187B ZA 200902187 A ZA200902187 A ZA 200902187A ZA 200902187 A ZA200902187 A ZA 200902187A ZA 200902187 B ZA200902187 B ZA 200902187B
Authority
ZA
South Africa
Prior art keywords
ethinylxanthine
selective
derivatives
receptor antagonists
antagonists
Prior art date
Application number
ZA200902187A
Other languages
English (en)
Inventor
Mueller Christa
Hockemeyer Joerg
Tzvetkov Nikolay
Burbiel Joachim
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Publication of ZA200902187B publication Critical patent/ZA200902187B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA200902187A 2006-12-22 2009-03-26 8-Ethinylxanthine derivatives as selective A2A receptor antagonists ZA200902187B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06026739A EP1939197A1 (fr) 2006-12-22 2006-12-22 Derivés de 8-éthinylxanthine comme antagonistes selectives du recepteur A2A

Publications (1)

Publication Number Publication Date
ZA200902187B true ZA200902187B (en) 2009-11-25

Family

ID=37733427

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200902187A ZA200902187B (en) 2006-12-22 2009-03-26 8-Ethinylxanthine derivatives as selective A2A receptor antagonists

Country Status (12)

Country Link
US (1) US8044061B2 (fr)
EP (2) EP1939197A1 (fr)
CN (1) CN101631788A (fr)
AR (1) AR064657A1 (fr)
AU (1) AU2007338413A1 (fr)
BR (1) BRPI0720419A2 (fr)
CA (1) CA2672692A1 (fr)
CO (1) CO6210727A2 (fr)
RU (1) RU2009127883A (fr)
UY (1) UY30835A1 (fr)
WO (1) WO2008077557A1 (fr)
ZA (1) ZA200902187B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1781657T3 (pl) * 2004-02-14 2013-08-30 Glaxosmithkline Ip Dev Ltd Leki o aktywności wobec receptora HM74A
WO2011101861A1 (fr) 2010-01-29 2011-08-25 Msn Laboratories Limited Procédé de préparation d'inhibiteurs de la dpp-iv
EP2465859A1 (fr) 2010-12-08 2012-06-20 Life & Brain GmbH Dérivés de 8-triazolylxanthine, leurs procédés de production et leur utilisation en tant qu'antagonistes du récepteur de l'adénosine
US9221821B2 (en) * 2012-06-05 2015-12-29 Forest Laboratories Holdings, Limited Methods for the synthesis of 1,3-substituted aminouracils and other xanthine-related compounds
GB201311107D0 (en) * 2013-06-21 2013-08-07 Univ Edinburgh Bioorthogonal methods and compounds
AU2014291161B2 (en) 2013-07-18 2018-04-26 Taiho Pharmaceutical Co., Ltd. Antitumor drug for intermittent administration of FGFR inhibitor
US10124003B2 (en) 2013-07-18 2018-11-13 Taiho Pharmaceutical Co., Ltd. Therapeutic agent for FGFR inhibitor-resistant cancer
GB2553685B (en) * 2015-03-27 2020-06-10 Latvian Inst Organic Synthesis Novel ethynylxanthines for use as inhibitors of matrix metalloproteinases and angiogenesis
CA2989161C (fr) * 2015-03-27 2022-03-01 Latvian Institute Of Organic Synthesis Ethynylxanthines, leurs preparations et leurs utilisations pour traiter le cancer
WO2016159747A1 (fr) 2015-03-27 2016-10-06 Latvian Institute Of Organic Synthesis Éthynylxanthines, préparation et utilisation de ces composés en tant que modulateurs des canaux calciques
PT3279202T (pt) 2015-03-31 2020-08-31 Taiho Pharmaceutical Co Ltd Cristal de composto de alquinilo de benzeno 3,5-dissubstituído
BR112017021386A2 (pt) * 2015-04-08 2018-07-03 Lewis And Clark Pharmaceuticals, Inc. carbamatos de alquinila com xantina substituída/carbamatos reversos como antagonistas de a2b.
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
EP3424505A4 (fr) 2016-03-04 2019-10-16 Taiho Pharmaceutical Co., Ltd. Préparation et composition de traitement de tumeurs malignes
JP6918204B2 (ja) 2018-03-19 2021-08-11 大鵬薬品工業株式会社 アルキル硫酸ナトリウムを含む医薬組成物
US20240002416A1 (en) 2020-10-15 2024-01-04 Rheinische-Friedrich-Wilhelms-Universität Bonn MRGPRX4 Agonists and Antagonists
CN115636831B (zh) * 2022-10-27 2024-11-08 中国药科大学 稠合嘧啶二酮类化合物、其用途以及药物组合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484920A (en) 1992-04-08 1996-01-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for Parkinson's disease
CA2161011A1 (fr) 1994-02-23 1995-08-31 Fumio Suzuki Derives de la xanthine
CA2369981A1 (fr) 1999-04-09 2000-10-19 Cell Therapeutics, Inc. Composes therapeutiques comme inhibiteurs de la signalisation de l'interleukine-12 et methodes d'utilisation de ces composes
EP1370562A1 (fr) 2001-02-14 2003-12-17 Warner-Lambert Company LLC Derives de thieno'2,3-d pyrimidinone utilises comme inhibiteurs de metalloproteinases matricielles
EP1368349B1 (fr) * 2001-02-24 2007-02-14 Boehringer Ingelheim Pharma GmbH & Co.KG Derives xanthine, fabrication et utilisations en tant qu'agents pharmaceutiques
AU2003253165A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
WO2004092177A1 (fr) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolopyrazines et procedes de preparation et d'utilisation ce celles-ci
WO2004092173A2 (fr) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Antagonistes de recepteur d'adenosine a2a
AU2005231440B9 (en) 2004-04-02 2012-02-23 Dogwood Pharmaceuticals, Inc. Selective antagonists of A2A adenosine receptors
WO2006091936A2 (fr) 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Procedes permettant d'effectuer la synthese de xanthines a substitution cycloalkyle dissymetrique
US7618962B2 (en) 2005-02-25 2009-11-17 Pgx Health, Llc Pyrazolyl substituted xanthines
US7579348B2 (en) 2005-02-25 2009-08-25 Pgxhealth, Llc Derivatives of 8-substituted xanthines
WO2006091896A2 (fr) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Xanthines substituees par pyridyle

Also Published As

Publication number Publication date
CO6210727A2 (es) 2010-10-20
AR064657A1 (es) 2009-04-15
EP1939197A1 (fr) 2008-07-02
CA2672692A1 (fr) 2008-07-03
AU2007338413A1 (en) 2008-07-03
CN101631788A (zh) 2010-01-20
WO2008077557A1 (fr) 2008-07-03
WO2008077557A8 (fr) 2009-05-22
UY30835A1 (es) 2008-07-31
US20080221134A1 (en) 2008-09-11
US8044061B2 (en) 2011-10-25
RU2009127883A (ru) 2011-01-27
BRPI0720419A2 (pt) 2013-12-31
EP2097415B1 (fr) 2014-10-29
EP2097415A1 (fr) 2009-09-09

Similar Documents

Publication Publication Date Title
ZA200902187B (en) 8-Ethinylxanthine derivatives as selective A2A receptor antagonists
IL201234A0 (en) Adenosine a2a receptor antagonists
IL195006A0 (en) Thiazolo-pyramidine/pyridine urea derivatives as adenosine a2b receptor antagonists
ZA200901036B (en) Adenosine derivatives as A2A receptor agonists
ZA200802588B (en) Imidazopyridine derivatives as A2B adenosine receptor antagonists
EP2058304A4 (fr) Antagoniste du récepteur p2x4
ZA200800320B (en) Indol-3-carbonyl-spiro-piperidine derivatives as Via receptor antagonists
IL194398A0 (en) Bisadenosine compounds as adenosine a2a receptor agonists
IL198650A0 (en) Progesterone receptor antagonists
EP2032797A4 (fr) Antagonistes du récepteur de l'adénosine a2b
PL2069310T3 (pl) Pochodne sulfonylopirazolino-1-karboksyamidyny jako antagoniści 5-HT6
ZA200806065B (en) Oxazoloisoquinoline derivatives as thrombin receptor antagonists
IL198334A0 (en) 2-phenyl-6-aminocarbonyl-pyrimidine derivatives and their use as p2y12 receptor antagonists
IL196536A0 (en) Selective antagonists of a2a adenosine receptors
ZA200903496B (en) Spiro-piperidine derivatives as via receptor antagonists
PT1912976E (pt) Derivados de indol-3-il-carboni-piperidin-benzimidazole como antagonistas dos receptores v1a
HU0501169D0 (en) New phenantridine derivatives as selective bradykinin b1 receptor antagonists
ZA200900627B (en) Selective antagonists of A2A adenosine receptors
HK1132499A (en) 8-ethinylxanthine derivatives as selective a2a receptor antagonists
HK1126187A (en) A2a adenosine receptor antagonists
HK1138592A (en) A2a adenosine receptor antagonists
HK1127059A (en) Adenosine a2a receptor antagonists
GB0605861D0 (en) A2B adenosine receptor antagonists
GB0705379D0 (en) A2b adenosine receptor antagonists
GB0505786D0 (en) A2b adenosine receptor antagonists